Dual-Responsive Nanomedicine Activates Programmed Antitumor Immunity through Targeting Lymphatic System
ACS Nano · 30.04.2024 · 18 (17) · 11070-11083
DOI: 10.1021/acsnano.3c11464 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Nano, online erschienen am 19.04.2024. Verfasst von Hong Xiao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Ultrasonic, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China. Hauptthemen laut MEDLINE: Nanomedicine. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Sun Yat-sen University, Key Technologies Research and Development Program of Guangzhou Municipality, Basic and Applied Basic Research Foundation of Guangdong Province.
Abstract (Originalsprache)
Effective antitumor immunotherapy depends on evoking a cascade of cancer-immune cycles with lymph nodes (LNs) as the initial sites for activating antitumor immunity, making drug administration through the lymphatic system highly attractive. Here, we describe a nanomedicine with dual responsiveness to pH and enzyme for a programmed activation of antitumor immune through the lymphatic system. The proposed nanomedicine can release the STING agonist diABZI-C2-NH2 in the LNs' acidic environment to activate dendritic cells (DCs) and T cells. Then, the remaining nanomedicine hitchhikes on the activated T cells (PD-1+ T cells) through binding to PD-1, resulting in an effective delivery into tumor tissues owing to the tumor-homing capacity of PD-1+ T cells. The enzyme matrix metalloproteinase-2 (MMP-2) being enriched in tumor tissue triggers the release of PD-1 antibody (aPD-1) which exerts immune checkpoint blockade (ICB) therapy. Eventually, the nanomedicine delivers a DNA methylation inhibitor GSK-3484862 (GSK) into tumor cells, and then the latter combines with granzyme B (GZMB) to trigger tumor cell pyroptosis. Consequently, the pyroptotic tumor cells induce robust immunogenic cell death (ICD) enhancing the DCs maturation and initiating the cascading antitumor immune response. Study on a 4T1 breast tumor mouse model demonstrates the prominent antitumor therapeutic outcome of this nanomedicine through creating a positive feedback loop of cancer-immunity cycles including immune activation in LNs, T cell-mediated drug delivery, ICB therapy, and tumor cell pyroptosis-featured ICD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Ultrasonic, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.
- Nanomedicine Research Center, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.
- PCFM Lab of Ministry of Education, School of Materials Science and Engineering, Sun Yat-sen University, Guangzhou 510275, China.
ORCID-Profile: Hong Xiao, Shisong Han, Jinsheng Huang, Xintao Shuai
Förderung
- Sun Yat-sen University
- Key Technologies Research and Development Program of Guangzhou Municipality
- Basic and Applied Basic Research Foundation of Guangdong Province
- National Natural Science Foundation of China
Zitieren
APA
Xiao, H., Li, X., Liang, S., Yang, S., Han, S., Huang, J., Shuai, X., & Ren, J. (2024). Dual-Responsive Nanomedicine Activates Programmed Antitumor Immunity through Targeting Lymphatic System. ACS Nano, 18(17), 11070-11083. https://doi.org/10.1021/acsnano.3c11464
Vancouver
Xiao H, Li X, Liang S, Yang S, Han S, Huang J, et al. Dual-Responsive Nanomedicine Activates Programmed Antitumor Immunity through Targeting Lymphatic System. ACS Nano. 2024;18(17):11070-11083. doi:10.1021/acsnano.3c11464
BibTeX
@article{Xiao2024,
author = {Xiao, Hong and Li, Xiaoxia and Liang, Simin and Yang, Shuguang and Han, Shisong and Huang, Jinsheng and Shuai, Xintao and Ren, Jie},
title = {Dual-Responsive Nanomedicine Activates Programmed Antitumor Immunity through Targeting Lymphatic System},
journal = {ACS Nano},
year = {2024},
volume = {18},
number = {17},
pages = {11070--11083},
doi = {10.1021/acsnano.3c11464}
}
EUVIMED